Pharmacogenetic aspects of the efficacy of nonsteroidal anti-inflammatory drugs and opioid analgesics for postoperative pain relief after total joint arthroplasty

Objective: to investigate possible associations between genetic, clinical, laboratory, and demographic parameters and the level of pain in the early postoperative (p/o) period, the need for opioid analgesics, and gastrointestinal symptoms in patients who underwent primary total knee (TKR) or hip replacement (THR).
Material and methods. Sixty-one patients hospitalized for THR or TKR were included in the study. P/o pain relief was achieved using nonsteroidal anti-inflammatory drugs (NSAIDs) – ketoprofen or ketorolac – with tramadol prescribed "on demand." Pain was assessed in all patients using the numeric rating scale (NRS) on postoperative days 1–5. The amount of opioid analgesics used during hospitalization was recorded. Gene polymorphisms of CYP2C9, CYP2C8, PTGS1, PTGS2, ABCB1, CYP2D6, OPRM1, COMT, and C3orf20 were analyzed using real-time polymerase chain reaction.
Results and discussion. Patients with the AC genotype of CYP2C9*3 experienced less intense pain on postoperative day 1 (4.5±1.0 vs. 7.0±2.3; p=0.03) and required fewer opioids during hospitalization (20.0±11.5 vs. 28.0±7.4 morphine equivalent units; p=0.04) compared to those with the AA genotype. Carriers of the CC genotype of the rs1045642 polymorphism of the ABCB1 gene reported less pain on day 5 (1.5±0.7 vs. 3.7±1.2; p=0.04) than those with the CT genotype. Patients with the AA genotype of rs1799971 in the OPRM1 gene required more opioids in p/o period than those with AG + GG genotypes (28.4±7.1 vs. 21.6±9.8 morphine equivalent units; p=0.03). Patients with the GG genotype of rs12496846 in the C3orf20 gene experienced more intense pain on p/o day 4 (6.0±1.41) than those with the AA genotype (2.60±1.50; p=0.002).
Conclusion. Following THR and TKR, pain intensity and/or opioid use were associated with patients’ pharmacogenetic profiles in CYP2C9, ABCB1, OPRM1, and C3orf20.

1. Halawi MJ, Grant SA, Bolognesi MP. Multimodal Analgesia for Total Joint Arthroplasty. Orthopedics. 2015 Jul 1;38(7):e616-25. doi: 10.3928/01477447-20150701-61.

2. Beverly A, Kaye AD, Ljungqvist O, et al. Essential Elements of Multimodal Analgesia in Enhanced Recovery After Surgery (ERAS) Guidelines. Anesthesiol Clin. 2017 Jun;35(2): e115-e143. doi: 10.1016/j.anclin.2017.01.018.

3. Hijos-Mallada G, Sostres C, Gomollуn F. NSAIDs, gastrointestinal toxicity and inflammatory bowel disease. Gastroenterol Hepatol. 2022 Mar;45(3):215-222. doi:10.1016/j.gastrohep.2021.06.003. Epub 2021 Jun 19.

4. Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020 Aug;108(2):191-200. doi: 10.1002/cpt.1830.

5. Zobdeh F, Eremenko II, Akan MA. Pharmacogenetics and Pain Treatment with a Focus on Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Antidepressants: A Systematic Review. Pharmaceut. 2022 Jun 1; 14(6):1190. doi: 10.3390/pharmaceutics14061190.

6. Figueiras A, Estany-Gestal A, Aguirre C, et al. CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study. Pharmacogenet Genomics. 2016 Feb;26(2):66-73. doi: 10.1097/FPC.0000000000000186.

7. Macias Y, Gomez TJ, Garcia-Martin E, et al. An update on the pharmacogenomics of NSAID metabolism and the risk of gastrointestinal bleeding. Expert Opin Drug Metab Toxicol. 2020 Apr;16(4):319-332. doi: 10.1080/17425255.2020.1744563. Epub 2020 Mar 29.

8. Glowka F, Karazniewicz-Lada M, Grzeskowiak E, et al. Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis. Eur J Drug Metab Pharmacokinet. 2011 Sep;36(3):167-73. doi: 10.1007/s13318-011-0041-1. Epub 2011 Apr 24.

9. David Rodrigues A. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos. 2005 Nov;33(11):1567-75. doi: 10.1124/dmd.105.006452. Epub 2005 Aug 23.

10. Ngo Suong NT, Addison CJ. Are COX-2 Selective NSAIDs Associated with Less GI, Renal, and Cardiovascular Side Effects: Evidence from Animals Treated with NSAIDs. Annual Research & Review in Bio. 2018;29(6): 1-8. doi: 10.9734/ARRB/2018/45152.

11. Arfeen M, Srivastava A, Srivastava N, et al. Design, classification, and adverse effects of NSAIDs: A review on recent advancements. Bioorg Med Chem. 2024 Oct 1:112: 117899. doi: 10.1016/j.bmc.2024.117899. Epub 2024 Aug 30.

12. Calvo AM, Zupelari-Goncalves P, Dionisio TJ, et al. Efficacy of piroxicam for postoperative pain after lower third molar surgery associated with CYP2C8*3 and CYP2C9. J Pain Res. 2017; Jul 6;10:1581-1589. doi: 10.2147/JPR.S138147.

13. Morton PG, Tarvin L. The Pain Game: pain assessment, management, and related JCAHO standards. Joint Commission on Accreditation of Health Care Organizations. J Contin Educ Nurs. 2001 Sep-Oct;32(5):223-7. doi: 10.3928/0022-0124-20010901-09.

14. Forgerini M, Urbano G, de Nadai TR, et al. Genetic Variants in PTGS1 and NOS3 Genes Increase the Risk of Upper Gastrointestinal Bleeding: A Case-Control Study. Front Pharmacol. 2021 Jul 5;12:671835. doi: 10.3389/fphar.2021.671835.

15. Sychev DA, Morozova TE, Shatskiy DA, et al. Effect of CYP2C9, PTGS-1 and PTGS-2 gene polymorphisms on the efficiency and safety of postoperative analgesia with ketoprofen. Drug Metab Pers Ther. 2022 Jun 15;37(4): 361-368. doi: 10.1515/dmpt-2021-0222. eCollection 2022 Dec 1.

16. Mejia-Abril G, Zubiaur P, NavaresGomez M, et al. Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism. Front Pharmacol. 2021 Apr 29; 12:660639. doi: 10.3389/fphar.2021.660639.

17. Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021 Oct;110(4):888-896. doi: 10.1002/cpt.2149.

18. Dean L, Kane M. Tramadol Therapy and CYP2D6 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, et al, editors. Medical Genetics Summaries. Bethesda: National Center for Biotechnology Information; 2012.

19. Firfirey F, September A, Shamley D. ABCB1 and OPRM1 Single-Nucleotide Polymorphisms Collectively Modulate Chronic Shoulder Pain and Dysfunction in South African Breast Cancer Survivors. Pharmacogen. 2022 Jun;23(9):513-530. doi: 10.2217/pgs-2022-0020.

20. Persson AKM, Pettersson FD, Еkeson J. Single Nucleotide Polymorphisms Associated with Pain Sensitivity After Laparoscopic Cholecystectomy. Pain Med. 2018 Jun 1; 19(6):1271-1279. doi: 10.1093/pm/pnx164.

21. Nishizawa D, Nagashima M, Kasai S, et al. Associations between the C3orf20 rs12496846 Polymorphism and Both Postoperative Analgesia after Orthognathic and Abdominal Surgeries and C3orf20 Gene Expression in the Brain. Pharmaceutics. 2022 Mar 28;14(4):727. doi: 10.3390/pharmaceutics14040727.

22. Halawi MJ, Grant SA, Bolognesi MP. Multimodal Analgesia for Total Joint Arthroplasty. Orthopedics. 2015 Jul 1;38(7):e616-25. doi: 10.3928/01477447-20150701-61

23. Hamilton WG, Gargiulo JM, Reynolds TR, Parks NL. Prospective Randomized Study Using Pharmacogenetics to Customize Postoperative Pain Medication Following Hip and Knee Arthroplasty. J Arthroplasty. 2022 Jun; 37(6S):S76-S81. doi: 10.1016/j.arth.2022.02.037. Epub 2022 Feb 18.

24. Chang RW, Tompkins DM, Cohn SM. Are NSAIDs Safe? Assessing the Risk-Benefit Profile of Nonsteroidal Anti-inflammatory Drug Use in Postoperative Pain Management. Am Surg. 2021 Jun;87(6):872-879. doi: 10.1177/0003134820952834. Epub 2020 Nov 26.

25. Karateev AE, Nasonov EL, Ivashkin VT. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-prakticheskaya revmatologiya. 2018;56:1-29. (In Russ.).

26. Muradian A, Sychev D, Blagovestnov D, et al. The effect of CYP2D6 and CYP2C9 gene polymorphisms on the efficacy and safety of the combination of tramadol and ketorolac used for postoperative pain management in patients after video laparoscopic cholecystectomy. Drug Metab Pers Ther. 2021 Jul 12; 37(1):27-34. doi: 10.1515/dmpt-2021-0112.

27. Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016 Feb;17(2):131-57. doi: 10.1016/j.jpain.2015.12.008.

28. Lavand'homme PM, Kehlet H, Rawal N, et al. PROSPECT Working Group of the European Society of Regional Anaesthesia and Pain Therapy (ESRA). Pain management after total knee arthroplasty: PROcedure SPEcific Postoperative Pain ManagemenT recommendations. Eur J Anaesthesiol. 2022 Sep 1; 39(9):743-757. doi: 10.1097/EJA.0000000000001691

29. Ovechkin AM. Postoperative anesthesia. Postoperative anesthesia. Methodological recommendations. Obshcherossiiskaya obshchestvennaya organizatsiya «Federatsiya anesteziologov i reanimatologov»; 2019. Р. 3-51.

30. Liu YC, Wang WS. Human mu-opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ultracet) in oxaliplatin-induced painful neuropathy. Cancer. 2012 Mar 15;118(6):1718-25. doi: 10.1002/cncr.26430. Epub 2011 Aug 11.

31. Nishizawa D, Nagashima M, Kasai S, et al. Associations between the C3orf20 rs12496846 Polymorphism and Both Postoperative Analgesia after Orthognathic and Abdominal Surgeries and C3orf20 Gene Expression in the Brain. Pharmaceutics. 2022 Mar 28;14(4):727. doi: 10.3390/pharmaceutics14040727.